Lindbrook Capital’s Cellectar Biosciences CLRB Stock Holding History

Lindbrook Capital’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-33	Closed	-$21K	–	1885
2020 Q4	$21K	Buy	+33	New	+$15.2K	0.01%	666

Other funds holding CLRB

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Lindbrook Capital's CLRB Position: Q1 2021 in Review

Lindbrook Capital sold out of Cellectar Biosciences (CLRB) in Q1 2021, closing a stake of 33 shares — an estimated $21K sold.

Lindbrook Capital first reported a position in CLRB in Q4 2020 and held it in 1 quarter. The position peaked at $21K in Q4 2020. 44 funds tracked by Wall St. Rank hold CLRB as of Q1 2021.

Lindbrook Capital reported no remaining Cellectar Biosciences position as of Q1 2021 after selling out during the quarter.
Lindbrook Capital sold 33 Cellectar Biosciences shares in Q1 2021, an estimated $21K.
Lindbrook Capital first reported a position in Cellectar Biosciences in Q4 2020 and held it in 1 quarter.
Lindbrook Capital's Cellectar Biosciences position peaked at $21K in Q4 2020.
44 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2021.

Based on Lindbrook Capital's 13F filing for Q1 2021, filed 28 Apr 2021.